UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037201
Receipt number R000042411
Scientific Title Effect of tablets containing whey peptides on rehydration
Date of disclosure of the study information 2019/06/27
Last modified on 2020/02/17 16:02:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of tablets containing whey peptides on rehydration

Acronym

Effect of tablets containing whey peptides on rehydration

Scientific Title

Effect of tablets containing whey peptides on rehydration

Scientific Title:Acronym

Effect of tablets containing whey peptides on rehydration

Region

Japan


Condition

Condition

Healthy adult males

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aimed to assess the effect of the tablets containing whey peptides on the decrease of body fluid in healthy men.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Plasma volume change, serum total protein, serum albumin, body weight change, urine volume, serum Na, serum osmolality, serum insulin, serum glucose, FENa, creatinine clearance, free water clearance, eardrum temperature, subjective symptoms (feelings of fatigue, thirst, pain in foot muscle, heat, and abdominal distension), POMS2

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Single dose administration of the test food in intervention period. The weight of administrated water is equal to the decreased body weight by the exercise. The number of taken tablets is one per 50 mL of administrated water.

Interventions/Control_2

In control test, oral ingestion of water whose volume is equal to the body weight loss by exercise.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

50 years-old >

Gender

Male

Key inclusion criteria

1) Subjects whose written informed consent has been obtained
2) Subjects who are males aged 20-49 years
3) Subjects whose BMI is between 18.5 and 25.0 kg/m2

Key exclusion criteria

1) Subjects who have serious or progressive diseases or symptoms
2) Subjects who have cardiovascular or kidney diseases
3) Subjects received dietary counselling
4) Subjects who cannot exercise with cycle ergometer
5) Subjects who have food allergy
6) Subjects who donated 200 mL blood within 1 month or 400 mL blood within 3 months before starting of this test
7) Subjects who joined other clinical tests within 1 month before starting of this test
8) Subjects who are smoker
9) Subjects judged inappropriate for this study by the principal

Target sample size

36


Research contact person

Name of lead principal investigator

1st name Shukuko
Middle name
Last name Ebihara

Organization

Chiyoda para medical care clinic

Division name

Chiyoda para medical care clinic

Zip code

101-0047

Address

2F, Sanwa-Uchikanda Bldg 3-3-5 Uchikanda, Chiyodaku, Tokyo 101-0047, Japan

TEL

03-5297-5548

Email

m.n@cpcc.co.jp


Public contact

Name of contact person

1st name Makoto
Middle name
Last name Yamaguchi

Organization

Meiji Co., Ltd.

Division name

Food Microbiology and Function Research Laboratories, R&D Division

Zip code

192-0919

Address

1-29-1 Nanakuni, Hachioji, Tokyo

TEL

042-632-5849

Homepage URL


Email

makoto.yamaguchi@meiji.com


Sponsor or person

Institute

Meiji Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Meiji Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Meiji Institutional Review Board

Address

1-29-1 Nanakuni, Hachioji, Tokyo 192-0919

Tel

042-632-5900

Email

MEIJI.IRB@meiji.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 06 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 06 Month 27 Day

Date of IRB

2019 Year 06 Month 26 Day

Anticipated trial start date

2019 Year 07 Month 19 Day

Last follow-up date

2019 Year 09 Month 15 Day

Date of closure to data entry

2019 Year 10 Month 18 Day

Date trial data considered complete

2019 Year 10 Month 24 Day

Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 06 Month 27 Day

Last modified on

2020 Year 02 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042411


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name